Document Detail


Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
MedLine Citation:
PMID:  15117110     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study compared the effects of two sympatholytic agents--one central (moxonidine) and one peripheral (atenolol)--on blood pressure and other metabolic syndrome factors in postmenopausal hypertensive women who were not taking hormone replacement therapy. Atenolol and moxonidine led to a statistically significant reduction in diastolic blood pressure of 9.5 mmHg and 5.5 mmHg, respectively. A clear rebound effect was observed in the atenolol patients whereas the moxonidine group exhibited a slightly further decrease in blood pressure. Moxonidine also caused a profound decrease in both mean plasma-glucose area under the curve (AUC) during oral glucose tolerance test (-0.96 mmol/L x H, NS) and mean plasma-insulin AUC (-6.15 mU/L x H). Therefore, moxonidine displayed a slightly less potent antihypertensive effect than atenolol in hypertensive postmenopausal women, but it demonstrated a better metabolic effect. To conclude, moxonidine could benefit hypertensive postmenopausal women who display other signs of metabolic syndrome.
Authors:
Risto Kaaja; Karin Manhem; Jaakko Tuomilehto
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical practice. Supplement     Volume:  -     ISSN:  1368-504X     ISO Abbreviation:  Int J Clin Pract Suppl     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-04-30     Completed Date:  2004-10-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9712380     Medline TA:  Int J Clin Pract Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  26-32     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use*
Atenolol / therapeutic use*
Blood Glucose / analysis
Double-Blind Method
Female
Humans
Hypertension / drug therapy*,  metabolism
Imidazoles / therapeutic use*
Imidazoline Receptors
Insulin / blood
Middle Aged
Postmenopause*
Prospective Studies
Receptors, Drug / metabolism
Sympatholytics / therapeutic use
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Blood Glucose; 0/Imidazoles; 0/Imidazoline Receptors; 0/Receptors, Drug; 0/Sympatholytics; 11061-68-0/Insulin; 29122-68-7/Atenolol; 75438-57-2/moxonidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The metabolic syndrome in women: implications for therapy.
Next Document:  Genetic epidemiological approaches in the study of risk factors for cardiovascular disease.